Indications for and utilization of ACE inhibitors in older individuals with diabetes: Findings from the national health and nutrition examination survey 1999 to 2002

Journal of General Internal Medicine

Volumn 21, Issue 4, 2006, Pages 315-319

  Rosen, Allison B ^a,b,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Cardiovascular disease; Diabetes; Performance measures; Quality of care; Renal disease; Secondary prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG INDICATION; DRUG UTILIZATION; FEMALE; HEALTH CARE QUALITY; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SMOKING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG UTILIZATION; FEMALE; HEALTH SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NUTRITION SURVEYS; RISK FACTORS; UNITED STATES;

EID: 33646229106     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2006.00351.x     Document Type: Article

References (45)

1. Mokdad AH Ford ES Bowman BA et al Diabetes trends in the US 1990-1998 Diab Care 2000 23 1278 83
2. Mokdad AH Bowman BA Ford ES Vinicor F Marks JS Koplan JP The continuing epidemics of obesity and diabetes in the United States JAMA 2001 286 1195 200
3. Medicare Current Beneficiary Survey. Self-reported health conditions and risk factors of Medicare beneficiaries, by age and gender, 2000. Available at Accessed April 12, 2004
4. Bertoni AG Krop JS Anderson GF Brancati FL Diabetes-related morbidity and mortality in a national sample of U.S. elders Diab Care 2002 25 471 5
5. Lewis EJ Hunsicker LG Bain RP Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 1993 329 1456 62
6. Ravid M Lang R Rachmani R Lishner M Long-term renoprotective effect of angiotensin-converting-enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study Arch Intern Med 1996 156 286 9
7. Ravid M Brosh D Levi Z Bar-Dayan Y Ravid D Rachmani R Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus Ann Intern Med 1998 128 982 8
8. Viberti G Mogensen CE Groop LC Pauls JF Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria JAMA 1994 271 275 9
9. Kvetny J Gregersen G Pedersen RS Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus Q J Med 2001 94 89 94
10. Ahmad J Siddiqui MA Ahamd H Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria Diab Care 1997 20 1576 81
11. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 2001 134 370 9
12. Haider A Oh P Peloso PM An evidence-based review of ACE inhibitors in incipient diabetic nephropathy Can J Clin Pharmacol 2000 7 115 9
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 2000 342 145 53
14. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy Lancet 2000 355 253 9
15. Niskanen L Hedner T Hansson L Lanke J Niklason A for the CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertiensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/[beta]-blocker-based treatment regimen a subanalysis of the Captopril prevention project Diab Care 2001 24 2091 6
16. Brenner BM Cooper ME de Zeeuw D et al Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 2001 345 861 9
17. Lewis EJ Hunsicker LG Clarke WR Berl T Pohl MA Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with neuropathy due to type 2 diabetes N Engl J Med 2001 345 851 60
18. Parving HH Lehnert H Brochner-Mortensen J Gomis R Andersen S Amer P Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 2001 345 870 8
19. Lindholm LH Ibsen H Dahlof B et al Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE) a randomized trial against atenolol Lancet 2002 359 1004 10
20. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria Lancet 1997 349 1787 92
21. Shlipak M Diabetic nephropathy Clin Evid 2005 13 149 54
22. Bennett PH Haffner S Kasiske BL et al Screening and management of microalbuminuria in patients with diabetes mellitus recommendations to the scientific advisory board of the national kidney foundation from an ad hoc committee of the council on diabetes mellitus of the national kidney foundation Am J Kidney Dis 1995 25 107 12
23. American Diabetes Association. Standards of medical care for patients with diabetes mellitus Diab Care 1997 20 supp 1 S5 S13
24. Konstam M Dracup K Baker D et al Heart failure evaluation and care of patents with left-ventricular systolic dysfunction In MA Konstam, ed. Clinical Practice Guideline No. 11 Rockville, MD Agency for Health Care Policy & Research 1994
25. American Diabetes Association. Standards of medical care in diabetes Diab Care 2005 28 suppl 1 S4 S36
26. Sixth report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure Arch Intern Med 1997 157 2413 42
27. NHANES 1999-2000 Data Release. Prescription medication subsection of dietary supplements and prescription medication section. Available at Accessed October 4, 2005
28. NHANES 2001-2002 Data Documentation: April 2005 Prescription medication subsection of dietary supplements and prescription medication section. Available at Accessed October 4, 2005
29. Paster RZ Snavely DB Sweet AR et al Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors Clin Therap 1998 20 978 89
30. Tanser PH Campbell LM Carranza JK Toutouzas P Watts R for the Multicentre Cough Study Group. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough Am J Hypertens 2000 13 214 8
31. NHANES. NHANES analytic guidelines: June 2004 version. Available at Accessed March 3, 2005
32. Goldberg RB Cardiovascular disease in patients who have diabetes Cardiol Clin 2003 21 399 413
33. Kramer HJ Nguyen QD Curhan G Hsu C Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus JAMA 2003 289 3273 7
34. Dunn EJ Burton CJ Feest TG The care of patients with diabetic nephropathy audit, feedback, and improvement Q J Med 1999 92 443 9
35. Gold JA A word from WIPRO improving use of ACE inhibitors in diabetic nephropathy Wisc Med J 1996 588 9
36. Scarsi KK Bjornson DC The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes Ann Pharmacother 2000 34 1002 6
37. Gordian ME Kelly J Why patients with diabetes, hypertension and/or proteinuria are NOT on angiotensin converting enzyme inhibitors Alaska Med 1998 40 51 4
38. Rosen AB Karter AJ Liu JY Selby JV Schneider EC Use of ACE-inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes J Gen Intern Med 2004 19 671 7
39. Gerstein HC Mann JFE Yi Q et al Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 2001 286 421 6
40. Haffner SM Lehto S Ronnemaa T Pyorala K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 1998 339 229 34
41. Hillen T Coshall C Tilling K Rudd AG McGovern R Wolfe CDA Cause of stroke recurrence is multifactorial patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register Stroke 2003 34 1457 63
42. Valmadrid CT Klein R Moss SE Klein BEK The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus Arch Intern Med 2000 160 1093 100
43. National Committee for Quality Assurance (NCQA). The state of managed care quality, 2001. Available at Accessed September 12, 2002
44. Bicket DP Using ACE inhibitors appropriately Am Fam Physician 2002 66 461 8
45. Reardon LC Macpherson DS Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998 158 26 32